PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate Cancers.
Diego TeyssonneauAntoine Thiery-VuilleminCharles DarianeEric BarretJean-Baptiste BeauvalLaurent BrureauGilles CréhangeGaëlle FiardGaëlle FromontMathieu GauthéAlain RuffionRaphaële Renard-PennaRomain MathieuPaul SargosMorgan RouprêtGuillaume PloussardGuilhem Roubaudnull On Behalf Of The Cc-Afu Cancerology Committee Of The Association Française d'UrologiePublished in: Journal of clinical medicine (2022)
Despite recent improvements in survival, metastatic castration-resistant prostate cancers (mCRPCs) remain lethal. Alterations in genes involved in the homologous recombination repair (HRR) pathway are associated with poor prognosis. Poly-ADP-ribose polymerase (PARP) inhibitors (PARPis) have demonstrated anti-tumoral effects by synthetic lethality in patients with mCRPCs harboring HRR gene alterations, in particular BRCA2 . While both olaparib and rucaparib have obtained government approvals for use, the selection of eligible patients as well as the prescription of these treatments within the clinical urology community are challenging. This review proposes a brief review of the rationale and outcomes of PARPi treatment, then a pragmatic vision of PARPi use in terms of prescription and the selection of patients based on molecular screening, which can involve potential genetic counseling in the case of associated germinal alterations.
Keyphrases
- poor prognosis
- end stage renal disease
- dna damage
- prostate cancer
- dna repair
- newly diagnosed
- ejection fraction
- chronic kidney disease
- small cell lung cancer
- long non coding rna
- prognostic factors
- primary care
- peritoneal dialysis
- gene expression
- type diabetes
- hepatitis c virus
- open label
- patient reported outcomes
- study protocol
- skeletal muscle
- hiv infected
- young adults
- combination therapy
- glycemic control
- patient reported